Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach, Cyosol, Battle Ready, rayovacAAA
Search This Board: 
Last Post: 9/14/2020 8:31:57 AM - Followers: 94 - Board type: Free - Posts Today: 0


 

Description:
Neurotrope Bioscience is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
For more information, visit: http://www.neurotrope.com/

Market Information (as of February 20, 2020):
Symbol: NTRP
Stock Price: $1.25
Market Cap: $24,685,410
Outstanding Shares: 19,748,328
Warrants, options & preferred stock:

Placement agent warrants 1 (expires November 13, 2020):
- 5,609 warrants exercisable at $0.32 ($1,795)
Series A warrants (expires November 16, 2020):
- 49,449 warrants exercisable at $0.32 ($15,824)
Series C warrants (expires November 16, 2020):
- 78,616 warrants exercisable at $0.32 ($25,157)

Series F warrants (expires November 16, 2021):
- 3,772,908 warrants exercisable at $12.80 ($48,293,222)
Placement agent warrants 2 (expires November 17, 2021):
- 382,887 warrants exercisable at $6.40 ($2,450,477)
 
Placement agent warrants 3 (expires August 23, 2023):
- 13,932 warrants exercisable at $0.32 ($4,458)
 
Advisor warrants 1 (expires June 1, 2024):
- 90,000 warrants exercisable at $7.13 ($641,700)
Advisor warrants 2 (expires June 5, 2024):
- 24,000 warrants exercisable at $7.12 ($170,880)
Placement agent and consultant warrants (expires June 19, 2024):
- 100,240 warrants exercisable at $6.25 ($626,500)

Placement agent warrants 4 (expires January 22, 2025):
- 200,000 warrants exercisable at $1.65 ($330,000)
 
Series E warrants (expires five years from the date of the initial exercise of the Series C Warrants):
- 819,914 warrants exercisable at $32.00 ($26,237,248)
Series G warrants (expires five years from the initial exercise date):
- 4,916,603 warrants exercisable at $4.37 ($21,485,555)
Series H warrants (expires five years from the initial exercise date):
- 10,909,100 warrants exercisable at $1.65 ($18,000,015)
Advisor warrants 3:
- 114,000 warrants exercisable at $5.31 ($605,340)
Advisor warrants 4:
- 114,000 warrants exercisable at $0.86 ($98,040)
Stock options:
- 2,296,981 options with a weighted average exercise price equal to $12.99 ($29,837,783)
Series D Convertible Preferred Stock:
- 7,277 shares convertible into an aggregate of 4,319,704 shares of common stock
 
To be raised from exercised warrants & options: $148,823,994
Fully Diluted Shares (Outstanding Shares + Warrants + Options Outstanding): 47,956,271
Fully Diluted Market Cap: $59,945,339

Reports:
Roth report: https://pdfhost.io/v/i@2x9BB+F_37943455120180308NTRPRothInitpdf.pdf
Maxim report: https://pdfhost.io/v/agpp@2Q+o_379427337NTRPinitiationpdf.pdf
Janney report: https://pdfhost.io/v/iQV43NGcT_413879072NTRPInitiation06182019pdf.pdf

Press Releases:
Phase 2a results: https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-its-phase-2a-study-of-bryostatin-1-in-alzheimers-disease-300038367.html

Exploratory Phase 2b results: https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-phase-2-study-of-bryostatin-1-for-moderate-to-severe-alzheimers-disease-300448563.html
Exploratory Phase 2b analysis: https://www.prnewswire.com/news-releases/neurotropes-bryostatin-improves-cognition-in-patients-with-advanced-alzheimers-disease-based-on-further-analysis-of-phase-2-clinical-trial-data-300578025.html

Confirmatory Phase 2b results: https://www.prnewswire.com/news-releases/neurotrope-announces-top-line-results-from-confirmatory-phase-2-study-of-bryostatin-1-in-moderate-to-severe-alzheimers-disease-300913655.html
Confirmatory Phase 2b analysis: https://www.prnewswire.com/news-releases/neurotrope-provides-corporate-update-after-completing-bryostatin-1-data-analysis-for-advanced-alzheimers-disease-trial-300991105.html

Scientific Articles:
[P2a & CU results] "Bryostatin Effects on Cognitive Function and PKC epsilon in Alzheimer’s Disease Phase IIa and Expanded Access Trials" (2017): https://pdfhost.io/v/XAcILs@Hc_jad2F20172F5822Fjad582jad1701612Fjad58jad170161pdf.pdf
[Exploratory P2b results] "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Ef?cacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease" (2018): https://pdfhost.io/v/GEa58CPiF_farlow2018pdf.pdf
[Memantine results] "Memantine in Moderate-to-Severe Alzheimer's Disease" (2003): https://www.nejm.org/doi/full/10.1056/NEJMoa013128
More scientific articles: https://pdfhost.io/v/.~Rt1cU63_bryo1.pdf

Patents:
Patents by Daniel L. Alkon: https://patents.justia.com/inventor/daniel-l-alkon
Patents by Daniel L. Alkon (grants only): http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L.&d=PTXT
Patents by Daniel L. Alkon (applications only): http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L&d=PG01

Media:
"A new era for treating diseases of the brain" (2008): https://youtu.be/W1pdg1kvQHI
"Rockefeller Institute drug provides hope for Alzheimer’s treatment" (2015): https://www.wvgazettemail.com/news/rockefeller-institute-drug-provides-hope-for-alzheimer-s-treatment/article_bf5bab5f-e40e-5f47-95ca-666f14b795e0.html
"The Scoop: Alzheimer’s Drug Tries to Build Up a Head of Steam" (2018): https://www.genengnews.com/magazine/the-scoop-alzheimers-drug-tries-to-build-up-a-head-of-steam/
"Advancements in Alzheimer’s Treatment: Interview with Dr. Daniel Alkon" (2018): https://newyork.legalexaminer.com/health/senior-care/advancements-in-alzheimers-treatment-interview-with-dr-daniel-alkon/
JPMorgan Alzheimer's Key Opinion Leader Call (2019): https://sndup.net/8rw4
Oppenheimer Alzheimer's Key Opinion Leader Call (2019): https://sndup.net/6pw6
"Company Seeks to Prove Marine-Derived Alzheimer's Drug Is No Fish Story" (2019): https://soundcloud.com/levine-media-group/company-seeks-to-prove-marine-derived-alzheimers-drug-is-no-fish-story
"Pizza Hut co-founder’s compassionate-care Alzheimer’s trial leads to hope for others" (2019): https://www.kansas.com/news/business/biz-columns-blogs/carrie-rengers/article229253744.html
"After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug" (2019): https://www.npr.org/sections/health-shots/2019/05/03/718754791/after-a-big-failure-scientists-and-patients-hunt-for-a-new-type-of-alzheimers-d
Dr. Alkon at Alzheimer's Solutions Conference (2019): https://www.youtube.com/watch?v=bP5GcAplXls
How an Alzheimer’s ‘cabal’ thwarted progress toward a cure (2019): https://www.scribd.com/document/414776750/Stat062519
Charles Ryan On Treating Alzheimer's Disease (2019): https://tdameritradenetwork.com/video/rB4AoWt8Hk2Ba5865CUHvQ
The Impacts of Alzheimer's Disease are Growing (2019): https://www.youtube.com/watch?v=x4NkJqASGZc
Ellis Martin Report with Neurotrope's Dr Daniel Alkon: Successfully Reversing Alzheimer's Disease? (2019): https://www.youtube.com/watch?v=KwkiUj2uGgA

Links:
Investor relations: http://www.neurotrope.com/ir/
Institutional ownership: https://www.nasdaq.com/symbol/ntrp/institutional-holdings
SEC filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001513856
SEC filings (Petros): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001815903
NTRP at Stocktwits: https://stocktwits.com/symbol/NTRP
NTRP at Investorvillage: https://www.investorvillage.com/smbd.asp?mb=19529
Bryostatin vs. Memantine vs. Placebo comparison: https://i.imgur.com/579PX0L.jpg
Test comparison: https://i.imgur.com/s61opUd.jpg
BryoLogyx: https://bryologyx.com/
NeuroDiagnostics: https://www.ndx-discern.com/
NTRP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP News: Quarterly Report (10-q) 08/10/2020 05:02:37 PM
NTRP News: Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, P... 07/30/2020 09:00:00 AM
NTRP News: Current Report Filing (8-k) 07/29/2020 05:16:50 PM
NTRP News: Current Report Filing (8-k) 07/24/2020 05:15:33 PM
NTRP News: Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) 07/24/2020 05:13:31 PM
PostSubject
#16267  Sticky Note NTRP IS A PUMP AND DUMP PENNY STOCK rayovacAAA 09/09/20 11:46:13 PM
#16239  Sticky Note Neurotrope is a front for old money and XenaLives 08/29/20 06:05:05 AM
#16205  Sticky Note FDA trial results. Includes Statistical plan and trial runncoach 07/08/20 08:25:53 PM
#16041  Sticky Note Neurotrope Launches New Long-Term Clinical Trial of Bryostatin Cyosol 05/28/20 09:07:14 AM
#16275   Ha ha. True. I'm just glad runncoach 09/14/20 07:36:42 AM
#16274   Thanks, much appreciated. Cyosol 09/14/20 03:44:13 AM
#16273   Passing this along Doc in case you have runncoach 09/13/20 12:29:30 PM
#16272   Thanks for the highlights Doc. Glad to runncoach 09/12/20 11:52:17 AM
#16271   I think the poster is only available to Doc328 09/12/20 11:11:18 AM
#16270   MSvirtual2020 conference included some info on bryostatin's remyelenation runncoach 09/12/20 08:54:11 AM
#16269   Ha Ha Ha...........Show me the "PUMP" LaurieM 09/10/20 08:39:28 PM
#16267   NTRP IS A PUMP AND DUMP PENNY STOCK rayovacAAA 09/09/20 11:46:13 PM
#16266   Laurie, Agreed, this is the anti-pump company and Battle Ready 09/09/20 03:07:49 PM
#16265   Ha ha ha........Please enlighten us? Where do LaurieM 09/09/20 01:25:42 PM
#16263   Thanks for the response, Battle Ready. Theburg 09/06/20 06:45:05 PM
#16262   I don't know if that is knowable at Battle Ready 09/06/20 01:50:04 PM
#16261   If you were planning on buying new shares Theburg 09/06/20 08:43:40 AM
#16260   Ask Frank Carney's wife. Can't wait til runncoach 09/04/20 04:09:22 PM
#16259   FYI - investing in a pump and dump XenaLives 09/04/20 03:56:23 PM
#16258   FYI, The conversation is re peoples lives not $$$. LaurieM 09/04/20 03:19:50 PM
#16257   Yeah will be a long and bumpy road runncoach 09/04/20 12:41:26 PM
#16256   Thanks for the link. Cyosol 09/04/20 10:53:22 AM
#16255   Yeah that's sad with your friends. runncoach 09/04/20 09:32:27 AM
#16254   I agree, the risk is spectacular, for everyone XenaLives 09/04/20 09:29:57 AM
#16253   That’s a bit of waiting saddest part when Whoopddew 09/04/20 09:04:14 AM
#16252   New trial now registered. Will take longer runncoach 09/03/20 05:25:56 PM
#16250   I'm with you Laurie! The risk/reward on Battle Ready 09/01/20 09:41:57 PM
#16249   NTRP Is NOT a Pump and dump, absolutely LaurieM 09/01/20 09:09:09 PM
#16246   Oh no did they really compare individual's before runncoach 08/30/20 07:47:19 PM
#16245   A POST-HOC ANALYSIS!!!!!!!! rayovacAAA 08/30/20 07:34:51 PM
#16244   NTRP IS A PUMP AND DUMP PENNY STOCK rayovacAAA 08/30/20 07:24:15 PM
#16243   NTRP RECEIVED ORPHAN DRUG DESIGNATION FOR FRAGILE X rayovacAAA 08/30/20 07:22:28 PM
#16242  Restored DOES THE FDA ROUTINELY GRANT FAST TRACK DESIGNATION rayovacAAA 08/30/20 07:16:39 PM
#16241  Restored I don't think NTRP investors care in the Battle Ready 08/29/20 07:27:36 PM
#16240   Not sure how much "ire" there is or runncoach 08/29/20 08:56:55 AM
#16239   Neurotrope is a front for old money and XenaLives 08/29/20 06:05:05 AM
#16238   Not that I know of but this one runncoach 08/25/20 06:46:42 PM
#16237   Will this new trial be Ph3? blu_1 08/25/20 04:44:29 PM
#16236   Yeah and for those interested in the CNS runncoach 08/17/20 04:13:12 PM
#16235   The issue is that they still haven't decided Cyosol 08/17/20 01:13:09 AM
#16234   Did not see any issues in the quarterly runncoach 08/10/20 06:17:18 PM
#16233   I hope there are. Would much prefer to runncoach 08/10/20 08:37:21 AM
#16232   Apparently there are issues with this alleged merger... XenaLives 08/10/20 08:32:12 AM
#16231   Likely will be but even still patience will runncoach 08/10/20 07:23:19 AM
#16230   Thanks Coach, Theburg 08/09/20 10:31:51 PM
#16229   I'm not sure I really posted an exact runncoach 08/09/20 01:28:40 PM
#16228   Runncoach, Theburg 08/09/20 01:02:29 PM
#16227   Yes it is. Maybe the merger is runncoach 08/06/20 03:51:14 PM
#16226   Hmmm bit of volume hit Whoopddew 08/06/20 03:09:11 PM
#16225   At least the PRd it this morning runncoach 07/30/20 09:07:03 AM
#16224   SEC filing a/h today,that's why: novicetrader 07/29/20 09:51:38 PM
#16223   Probably some type of share price arbitrage relating runncoach 07/29/20 07:41:37 PM
#16222   WTF was thar AH spike about? HANUMAN 07/29/20 06:58:20 PM
#16221   Looks like the Worldwide Clinical Trials group has runncoach 07/29/20 05:27:22 PM
PostSubject
Consent Preferences